GGrantIndex
← Search

TRIAL OF ORAL CALCIMIMETIC AGENT AMG 073 IN HYPERPARATHY

$0M01FY2000RRNIH

University Of Chicago, Chicago IL

Investigators

Linked publications & trials

Abstract

This phase 2, randomized, double-blind, placebo-controlled, multicenter trial is designed to evaluate the safety, tolerability, pharmacokinetics, and clinical effects of multiple oral doses of AMG 073 in adult males and females with primary hyperparathyroidism. Subjects will receive daily doses of AMG 073 of between 50 mg and 175 mg or placebo.

View original record on NIH RePORTER →